These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 87722)

  • 1. Mutagenicity in urine of nurses handling cytostatic drugs.
    Falck K; Gröhn P; Sorsa M; Vainio H; Heinonen E; Holsti LR
    Lancet; 1979 Jun; 1(8128):1250-1. PubMed ID: 87722
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs.
    Tuffnell PG; Gannon MT; Dong A; DeBoer G; Erlichman C
    Am J Hosp Pharm; 1986 Feb; 43(2):344-8. PubMed ID: 3513557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Handling antineoplastic agents: urine mutagenicity in nurses.
    Rogers B; Emmett EA
    Image J Nurs Sch; 1987; 19(3):108-13. PubMed ID: 3311973
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of handling injectable antineoplastic agents.
    Anderson RW; Puckett WH; Dana WJ; Nguyen TV; Theiss JC; Matney TS
    Am J Hosp Pharm; 1982 Nov; 39(11):1881-7. PubMed ID: 6756133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of the salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drugs.
    Friederich U; Molko F; Hofmann V; Scossa D; Hann D; Würgler FE; Senn HJ
    Eur J Cancer Clin Oncol; 1986 May; 22(5):567-75. PubMed ID: 3533554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Handling of cytostatic drugs and urine mutagenesis.
    Poyen D; De Méo MP; Botta A; Gouvernet J; Duménil G
    Int Arch Occup Environ Health; 1988; 61(3):183-8. PubMed ID: 3220590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking.
    Bos RP; Leenaars AO; Theuws JL; Henderson PT
    Int Arch Occup Environ Health; 1982; 50(4):359-69. PubMed ID: 6757139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological monitoring of occupational exposure to mutagenic chemicals in the rubber industry. Use of the bacterial urinary mutagenicity assay.
    Falck K
    Scand J Work Environ Health; 1983; 9 Suppl 2():39-42. PubMed ID: 6356339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of genotoxic risk of handling cytostatic drugs in clinical pharmacy practice.
    Guinée EP; Beuman GH; Hageman G; Welle IJ; Kleinjans JC
    Pharm Weekbl Sci; 1991 Apr; 13(2):78-82. PubMed ID: 1870947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nurses' exposure to cytostatics in the handling of cytostatics. Theoretical lesson and clinical study].
    Johansson I; Bergenfelz A; Wadbo M
    SHSTF; 1981 Aug; (7):1-29. PubMed ID: 6914812
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures.
    Everson RB; Ratcliffe JM; Flack PM; Hoffman DM; Watanabe AS
    Cancer Res; 1985 Dec; 45(12 Pt 1):6487-97. PubMed ID: 4063994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutagenicity in urine from nurses handling cytostatic agents.
    Benhamou S; Callais F; Sancho-Garnier H; Min S; Courtois YA; Festy B
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1489-93. PubMed ID: 3595674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents.
    Connor TH; Theiss JC; Anderson RW; Puckett WH; Matney TS
    Am J Hosp Pharm; 1986 May; 43(5):1236-9. PubMed ID: 3521267
    [No Abstract]   [Full Text] [Related]  

  • 14. Occupational handling of cytostatic drugs.
    Kolmodin-Hedman B; Hartvig P; Sorsa M; Falck K
    Arch Toxicol; 1983 Sep; 54(1):25-33. PubMed ID: 6639351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occupational exposure to cyclophosphamide.
    Hirst M; Tse S; Mills DG; Levin L; White DF
    Lancet; 1984 Jan; 1(8370):186-8. PubMed ID: 6141334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion of mutagens following chemotherapy.
    Maniar AC; Williams TW; Hammond GW; Johnson N; Kobrinsky NL
    Am J Pediatr Hematol Oncol; 1991; 13(2):160-3. PubMed ID: 2069224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of methods for the biomonitoring of nurses handling antitumor drugs.
    Thiringer G; Granung G; Holmén A; Högstedt B; Järvholm B; Jönsson D; Persson L; Wahlström J; Westin J
    Scand J Work Environ Health; 1991 Apr; 17(2):133-8. PubMed ID: 2047815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety for the handling of cytostatic substances. Protective measures are useful].
    Schmid B
    Krankenpfl Soins Infirm; 1985 Jul; 78(7):39-41, 66-8. PubMed ID: 3850203
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutagenicity of urine from greenhouse workers.
    Shane BS; Scarlett-Kranz JM; Reid WS; Lisk DJ
    J Toxicol Environ Health; 1988; 24(4):429-37. PubMed ID: 3045336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ascorbic acid prophylaxis on the frequency of chromosome aberrations, urine mutagenicity and nucleolus test in workers occupationally exposed to cytostatic drugs.
    Rössner P; Cerná M; Pokorná D; Hájek V; Petr J
    Mutat Res; 1988 Jul; 208(3-4):149-53. PubMed ID: 3398866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.